ALMR · Alamar Biosciences, Inc.
$25.27
-0.64 (-2.47%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$1.80B
Shares
69.39M
Volume · Oct 9
1.13M
Avg daily vol (3M)
422.31K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$25.27
Open$25.97
Day$24.23–26.60
Available close range$19.09–38.13
Avg vol 30d558K
Short int2.8M · 4.1% float · 4.3d
Short vol38%
Last earningsAug 10, 2026
DataApr 2026–Oct 2026
Filing10-Q · Aug 11
The closing range uses available history since Apr 17, 2026; less than a full year is stored.
Up next
filed Aug 11, 2026
call held Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+82.1%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$250.05M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+414.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.1%
Latest settlement · 4.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−19%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
32%
mid-range
Momentum
relative strength
1-month return
−9%
trailing
6-month return
+15%
trailing
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
2 of 87 funds reported for Sep 30 · net +27 sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.05% of float · ▲ +32.4% MoM · 4.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
87 holders — 13F breadth
Squeeze score
51
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
Revenue
· full year 2026
Initiated
$116M – $120M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−19%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
32%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
2 of 87 funds reported for Sep 30 · net +27 sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.05% of float · ▲ +32.4% MoM · 4.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
87 holders — 13F breadth
Price context
position in its available closing range
Range low $19
Now $25 · 32%
Range high $38
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin | 60% | Q2 2026 | +13.2% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALMR
this stock
Alamar Biosciences, Inc.
|
$1.80B | — | — | — | 4.1% |
|
ABT
Abbott Laboratories
|
$171.55B | -20.5% | +5.7% | 27.6 | 0.8% |
|
MDT
Medtronic plc
|
$113.18B | -7.9% | +8.4% | 21.8 | 3.1% |
|
SYK
Stryker Corp
|
$106.38B | -21.1% | +11.2% | 28.7 | 1.5% |
|
BSX
Boston Scientific Corp
|
$61.07B | -55.2% | +12.5% | 17.1 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALMR | -26.5% | -9.4% | +14.9% | -25.8% | — |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -27.6% | -11.3% | +5.0% | -27.9% | — |